10x Genomics Inc. 2026年季度报告

SECURITIES AND EXCHANGE COMMISSION (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period endedMarch31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 10x Genomics, Inc. (Exact name of registrant as specified in its charter) 94588(Zip Code) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2of theExchange Act. Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2of theExchange Act).Yes☐No☒ As of April30, 2026, the registrant had 116,877,317 shares of Class A common stock, $0.00001 par value per share, outstanding and10,078,872 shares of Class B common stock, $0.00001 par value per share, outstanding. Table of Contents PARTI.FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited) Condensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Comprehensive LossCondensed Consolidated Statements of Stockholders’Equity 6Condensed Consolidated Statements of Cash Flows7Notes to Condensed Consolidated Financial Statements8 10x Genomics, Inc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”),and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to those sections’ “safeharbor.” All statements, other than historical facts, may be forward-looking statements. Forward-looking terminology such as “may,”“might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,”“estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or variations of these terms or similar terminology generallycan identify forward-looking statements, but the absence of these words is not determinative. These forward-looking statementsinclude statements regarding 10x Genomics, Inc.’s expectations regarding our plans, objectives, goals, beliefs, business strategies,acquisition of Scale Biosciences, Inc., results of operations, financial position, sufficiency of our capital resources, business outlook, The material risks, uncertainties and other factors that could affect 10x Genomics, Inc.’s financial and operating results and causeactual results to differ from those indicated by the forward-looking statements made include those described in the section titled “RiskFactors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report andPart I, Item 1A of our Annual Report on Form 10-K for the year ended December31, 2025. Our periodic filings are accessible on theU.S. Securities and Exchange Commission's (“SEC”) website at www.sec.gov. Although we believe the expectations reflected in theforward-looking statements are reasonable, new risks and uncertainties may emerge, and it is not possible for us to predict their impact Unless otherwise stated or the context otherwise indicates, references to “we,” “us,” “our,” “the Company,” “10x” and similarreferences refer to 10x Genomics, Inc. and its subsidiaries. Channels for Disclosure of Information Investors and others should note that we may announce material information to the public through filings with the SEC, our website(https://www.10xGenomics.com),press releases,public conference calls,public webcasts and our social media accounts(https://www.linkedin.com/company/10xgenomics,https://X.com/10xGenomics,https://www.facebook.com/10xGenomics,https://bsky.app/profil